Xrf Scientific Limited · ASX:XRF

Xrf Scientific — Shareholder Meeting (November 2011)

16 slides from Xrf Scientific's shareholder meeting presentation, Nov 30, 2011

  1. Slide 1: 2011 Annual General Meeting

    For personal use only 2011 Annual General Meeting 30 November 2011

  2. Slide 2: Disclaimer

    Disclaimer For personal use only No responsibility for contents of Investor Presentation •To the maximum extent permitted by law, XRF Scientific Limited and representatives: •make k no representation, t ti warranty t or undertaking, d t ki express or iimplied, li d as tto th the adequacy, d accuracy

  3. Slide 3: Corporate Snapshot

    Corporate Snapshot For personal use only Structure • Shares on issue: 128,823,764 • Share price: 19.5c • Market k cap: $2$25.1m 1 Directors • Ken Baxter – Non Executive Chairman • Terry Sweet – Managing Director • David Brown – Non Executive Director • John Parsons – Non Executive Director 2,635 20,

  4. Slide 4: Company Overview

    Company Overview For personal use only ƒ Manufacturer of consumables and equipment for mining and industry, for X‐Ray Fluorescence (XRF) analysis ƒ Offices in Perth and Melbourne with 60 employees across Australia X‐Ray Flux and Platinum Labware Specialised furnaces chemicals and general laboratory

  5. Slide 5: Blue Chip Client Base

    Blue Chip Client Base For personal use only 5

  6. Slide 6: Our Products

    For personal use only Our Products 6

  7. Slide 7: 2011 Operating Highlights

    2011 Operating Highlights For personal use only ƒ Acquired Sigma Flux and Precious Metals for $7m total consideration ƒ Rebranded operating divisions from old historical name’s to XRF Chemicals, XRF Labware and XRF Technology ƒ Greater margins achieved through XRF Chemicals and XRF Labware divisions

  8. Slide 8: 2011 Operating Highlights

    2011 Operating Highlights For personal use only Subsequent Events to 30 June 2011 ƒ Acquisition of 19.9% interest in Canadian flux manufacturer Scancia completed in August 2011 ƒ Placement and Share Purchase Plan of $4.34m successfully completed in July / August 2011 at 21.5 cents per share ƒ The Co

  9. Slide 9: FY2011 Financial Results

    FY2011 Financial Results For personal use only Highlights: ƒ Revenue up 12.7% on high range of guidance of $18m to $20.3m ƒ Profit before tax up 23.3% on high range of guidance of $3m to $3.7m ƒ Fully franked dividend of 1 cent per share, paid on 28 October 2011 2011 2010 Actuals Actuals Change $M $

  10. Slide 10: FY2011 Financial Results

    FY2011 Financial Results For personal use only Growth Drivers: 2,700 1,228 5,124 1,982 12,478 12,478 522 522 2010 2011 2010 2011 Sales Revenue ($'000) NPBT ($'000) Base amount Organic growth Sigma acquisition 10

  11. Slide 11: FY2011 Divisional Performance

    FY2011 Divisional Performance For personal use only 6,517 3,079 2,961 2,654 Highlights: ƒ Acquisition of Sigma Flux completed on 30 July 2011 08 09 10 11 ƒ Record demand experienced for the divisions primary product, Sales Revenue ($'000) x‐ray flux, as sample throughput in commercial laboratories w

  12. Slide 12: FY2011 Divisional Performance

    FY2011 Divisional Performance For personal use only 8,644 7,556 7,016 5,393 Highlights: ƒ Acquisition of Sigma Precious Metals completed on 30 July 2011 08 09 10 11 Sales Revenue ($'000) ƒ Rapid growth experienced in sale of new labware items 1,538 ƒ Increased amount of re‐manufacture and repairs re

  13. Slide 13: FY2011 Divisional Performance

    FY2011 Divisional Performance For personal use only 6,651 4,931 4,904 3,959 Highlights: ƒ 2011 results are in line with the end of a technological cycle of older products, with the cycle forecast to swing back upwards 08 09 10 11 with new products such as the Fusomatic 15 and Robotic Fusion Sales Re

  14. Slide 14: FY2012 Outlook

    FY2012 Outlook For personal use only ƒ Sales YTD are up strongly on the prior corresponding period (PCP): XRF Chemicals • Total sales revenue for 31/10/2011 / / YTD of $ $2.3m, up 27.8% (PCP: $1.8m) $ • Includes 4 months with Sigma Flux with PCP only including 3 XRF Labware • Total sales revenue for

  15. Slide 15: FY2012 Outlook

    FY2012 Outlook For personal use only ƒ Improving sales of capital equipment, with a significant technological break through with the “Fusomatic 15” fusion furnace ƒ Continue focus of expanding geographically, by increasing sales into areas such as Brazil and Africa ƒ Implementation of new accounting

  16. Slide 16: Questions?

    For personal use only Questions? 16

XRF Scientific — Shareholder Meeting (November 2011) on 6ix